ArticleThe Journal of infectious diseases2017
Transition Planning For After Polio Eradication.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Trial
- Flexibly funding WHO? An analysis of its donors' voluntary contributions.BMJ global health · 2023Article
- A qualitative exploration of the contributions of Polio Eradication Initiative to the Nigerian health system: policy implications for polio transition planning.Tropical medicine and health · 2022Article
- Culture-Independent Detection of Poliovirus in Stool Samples by Direct RNA Extraction.Microbiology spectrum · 2021Article
- A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy.Journal of medical Internet research · 2020Article
- Synthesis and translation of research and innovations from polio eradication (STRIPE): initial findings from a global mixed methods study.BMC public health · 2020Article
- Leveraging investments in Ebola preparedness for COVID-19 in Sub-Saharan Africa.AAS open research · 2020Article
- Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis.BMJ open · 2019Article
- A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5.Emerging microbes & infections · 2018Article
- Letting Go: Conceptualizing Intervention De-implementation in Public Health and Social Service Settings.American journal of community psychology · 2018Review
- The contribution of the polio eradication initiative on the operations and outcomes of non-polio public health programs: a survey of programs in the African region.The Pan African medical journal · 2018Article
- Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach.Expert review of vaccines · 2017Review
- Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.The Journal of infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The Global Polio Eradication Initiative (GPEI) has been in operation since 1988, now spends $1 billion annually, and operates through thousands of staff and millions of volunteers in dozens of countries. It has brought polio to the brink of eradication. After eradication is achieved, what should happen to the substantial assets, capabilities, and lessons of the GPEI? To answer this question, an extensive process of transition planning is underway. There is an absolute need to maintain and mainstream some of the functions, to keep the world polio-free. There is also considerable risk-and, if seized, substantial opportunity-for other health programs and priorities. And critical lessons have been learned that can be used to address other health priorities. Planning has started in the 16 countries where GPEI's footprint is the greatest and in the program's 5 core agencies. Even though poliovirus transmission has not yet been stopped globally, this planning process is gaining momentum, and some plans are taking early shape. This is a complex area of work-with difficult technical, financial, and political elements. There is no significant precedent. There is forward motion and a willingness on many sides to understand and address the risks and to explore the opportunities. Very substantial investments have been made, over 30 years, to eradicate a human pathogen from the world for the second time ever. Transition planning represents a serious intent to responsibly bring the world's largest global health effort to a close and to protect and build upon the investment in this effort, where appropriate, to benefit other national and global priorities. Further detailed technical work is now needed, supported by broad and engaged debate, for this undertaking to achieve its full potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.